Loading...
Back to narrative

HYPR: Expanded Clinical Use And Subscription Platform Will Drive Future Upside

HYPR: International Approvals And Expanded Use Will Drive Upside Momentum

HYPR logo
HYPR
AnalystConsensusTarget
Not Invested
Published 09 Apr 2025

Update shared on 04 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
11.8%
7D
4.0%

Analysts have maintained their price target for Hyperfine at 1.65 dollars, reflecting largely unchanged views on the company. Slight improvements in discount rate and profit margin estimates are offset by a marginally lower future earnings multiple.

What's in the News

  • Management issued revenue guidance for the fourth quarter of 2025 at approximately 5 to 6 million dollars, implying about 60 percent sequential and 137 percent year over year growth at the midpoint, and projected full year 2025 revenue of roughly 13 to 14 million dollars (company guidance).
  • The company announced plans to expand clinical use of its Swoop portable MRI system into the neurosurgical operating room. This is supported by the PRISM PMR study evaluating pre and post procedure imaging and potential for faster discharge and recovery (product announcement).
  • Hyperfine launched PULSE, a subscription platform giving Swoop users access to research imaging sequences powered by Optive AI software, community developed sequences, and raw data to accelerate innovation in portable MRI (product announcement).
  • Hyperfine filed and then completed a 17.5 million dollar follow on equity offering of Class A common stock and pre funded warrants, issuing 14 million shares at 1.25 dollars per share (financing filing).
  • Lock up agreements were disclosed for more than 63.5 million Class A shares, 15.1 million Class B shares, and related options, RSUs, and warrants, with restrictions scheduled to end on 15 December 2025 (lock up disclosure).

Valuation Changes

  • Fair Value Estimate: unchanged at 1.65 dollars per share, indicating no revision to the intrinsic value assessment.
  • Discount Rate: fallen slightly from 7.77 percent to approximately 7.70 percent, reflecting a modestly lower required return.
  • Revenue Growth: effectively unchanged, edging down marginally from about 46.56 percent to 46.55 percent.
  • Net Profit Margin: risen slightly from roughly 13.38 percent to 13.39 percent, implying a small improvement in long term profitability assumptions.
  • Future P/E: declined slightly from about 55.09 times to 54.97 times, modestly lowering the valuation multiple applied to forward earnings.

Have other thoughts on Hyperfine?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.